- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02071966
Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS (TIGER-M)
Effects of TIcaGREloR on Circulating Microparticles and Micro-RNAs in Patients With Non ST Elevation Acute Coronary Syndromes
The aim of the study is to learn more about the pathophysiology of acute coronary syndrome (ACS) and to evaluate the mechanisms responsible of the action and benefits of ticagrelor.
Ticagrelor is an oral and reversible inhibitor of P2Y12 receptor. Few information is available about the action of ticagrelor on the molecules involved in thrombogenesis and platelets activation in ACS.
The aim of this study is to evaluate the mechanisms of ticagrelor action in vivo.
It was observed that patients with myocardial infarction have higher blood levels of microparticles than patients with unstable angina or stable angina.
The investigators assumed that ticagrelor benefits are represented by a reduction of microparticle levels, a marker of endothelial dysfunction in patients with cardiovascular disease, and by a modification in microRNAs pattern, fragments of mRNA that have a regulatory action in various cellular processes (such as proliferation, differentiation, growth and cellular death) and represent new biomarkers in ACS.
Study Overview
Status
Intervention / Treatment
Detailed Description
Ticagrelor is an oral, reversibly binding P2Y12 receptor inhibitor that yields, in a dose-dependent fashion, greater and more consistent inhibition of platelet aggregation than standard regimens of clopidogrel in patients with stable atherosclerotic disease and ACS. However, little information is available regarding its complex effect on thrombogenesis and platelet activation in acute coronary syndromes setting. It has been widely demonstrated the potential role of MP in several biologic processes known to take part to pathophysiology of coronary syndromes, such as inflammation, coagulation and apoptosis. Recent studies focused on miRNAs' regulatory activity of several cellular processes, such as proliferation, differentiation, development, and cell death, and on their role as biomarkers in ACS. The investigators suppose that the observed major efficacy of ticagrelor is related to its actions on MP and microRNAs. Considering the major clinical effectiveness shown by ticagrelor in comparison with clopidogrel, the investigators hypothesize a more pronounced MP levels reduction as a possible mechanism for ticagrelor clinical benefits. Moreover, on the basis of the last evidences of microRNA involvement in the ACS pathophysiology, the investigators aim to assess the effect of ticagrelor on microRNA expression, in order to provide evidences for pleiotropic actions of this drug, which could partially explain its major efficacy in reduction of cardiovascular events in ACS patients.
In summary, principal hypothesis of the study are:
- Considering that ticagrelor is a stronger P2Y12 receptor inhibitor than clopidogrel, the investigators suppose that an increased inhibition of P2Y12 receptor by ticagrelor could reduce circulating levels of platelet and endothelial MP.
- In consideration of the observed role of microRNAs in expression of P2Y12 receptor, the investigators speculate that patient's susceptibility to P2Y12 receptor inhibitors could be influenced by microRNAs levels. Moreover, the investigators suppose that ticagrelor could influence microRNAs levels, considered as marker of cardiovascular risk
Aims of the study are:
- to assess MP levels variation in Non ST-Elevation Acute Coronary Syndromes (NSTE-ACS) patients treated with ticagrelor in addition to low or high acetyl-salicylic acid (ASA), in comparison with clopidogrel+ASA treatment, to demonstrate that major clinical efficacy of ticagrelor could be partially attributed to its influence on release of MP, that have an important role in coronary instability.
- to evaluate microRNAs levels variation in Non ST-Elevation Acute Coronary Syndromes (NSTE-ACS) patients treated with ticagrelor in addition to low or high ASA, in comparison with clopidogrel+ASA treatment, and to study possible correlations between microRNAs and MP levels, supposing that the ability of ticagrelor in reduced MP level could be related with microRNAs expression.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Rome, Italy, 00168
- Policlinico "A.Gemelli"
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- NSTE-ACS
- Male, 50-80 years old
- Female, postmenopausal age
Exclusion Criteria:
- Female, premenopausal age
- autoimmune disease
- infectious disease
- neoplasms
- diabetes
- chronic renal failure
- moderate or severe liver insufficiency
- GRACE risk score>140
- ACS or cerebrovascular accidents in previous three months
- in-stent restenosis
- surgery or trauma in previous three months
- active bleeding
- fibrinolytic therapy within 24 hours before randomization
- need for oral anticoagulation therapy
- an increased risk of bradycardia
- drugs study hypersensitivity (including aspirin)
- co-administration of ticagrelor or clopidogrel with strong CYP3A4 inhibitors
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Ticagrelor
Ticagrelor: oral, 180 mg once for the first dose then 90 mg twice a day
|
Comparison of Ticagrelor with another anti-platelet drug (Clopidogrel)
Other Names:
|
Active Comparator: Clopidogrel
Clopidogrel: oral, 300 or 600 mg once for the first dose, 75 mg once a day
|
Comparison of Clopidogrel with another anti-platelet drug (Ticagrelor)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Micro-RNA and microparticles
Time Frame: up to three months
|
up to three months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Luigi M Biasucci, Professor, Catholic University of the Sacred Heart
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Disease
- Syndrome
- Acute Coronary Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Ticagrelor
- Clopidogrel
Other Study ID Numbers
- D5130L00028
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non ST Segment Elevation Acute Coronary Syndrome
-
Stony Brook UniversityHennepin County Medical Center, MinneapolisUnknownAcute Coronary Syndrome | STEMI | NSTEMI - Non-ST Segment Elevation MI | Non ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Coronary Artery Thrombosis (Diagnosis) | Non ST Segment Elevation Acute Coronary Syndrome and other conditionsUnited States
-
Maastricht University Medical CenterVieCuri Medical CentreRecruitingNSTEMI - Non-ST Segment Elevation MI | ACS - Acute Coronary SyndromeNetherlands
-
Collegium Medicum w BydgoszczyRecruitingST Elevation Myocardial Infarction | Non ST Segment Elevation Acute Coronary SyndromePoland
-
General Hospital of Chinese Armed Police ForcesCompletedNon ST Segment Elevation Acute Coronary SyndromeChina
-
Karolinska InstitutetThe Swedish Research Council; Swedish Heart Lung Foundation; Swedish Foundation...CompletedAcute Coronary Syndrome | Angina, Unstable | Acute ST Segment Elevation Myocardial Infarction | Non-ST Elevation (NSTEMI) Myocardial InfarctionSweden
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedNon ST Segment Elevation Acute Coronary SyndromeNetherlands
-
Medical Center of South ArkansasWithdrawnAcute Coronary Syndrome | Acute ST Segment Elevation Myocardial InfarctionUnited States
-
University of North Carolina, Chapel HillCompletedMyocardial Infarction | Angina, Stable | Acute Coronary Syndrome | ST-segment Elevation Myocardial Infarction (STEMI) | Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)United States
-
An-Najah National UniversityCompletedMyocardial Infarction | Myocardial Ischemia | Coronary Artery Disease | Chest Pain | Angina, Stable | Acute Coronary Syndrome | Angina, Unstable | Non ST Segment Elevation Myocardial Infarction | ST-segment Elevation Myocardial Infarction (STEMI) | Non STEMI | Atheroscleroses, Coronary | Atherosclerotic Heart...Palestinian Territory, occupied
-
Catcronic Salut SLCompletedAngina, Unstable | ST-segment Elevation Myocardial Infarction (STEMI) | Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)Spain
Clinical Trials on Ticagrelor
-
Collegium Medicum w BydgoszczyCompleted
-
Federico II UniversityAdvicePharma GroupCompletedMyocardial Infarction | Coronary Artery Disease | Acute Coronary Syndrome | STEMI | NSTEMIItaly
-
University of FloridaCompleted
-
AstraZenecaParexelCompletedSickle Cell DiseaseGermany
-
University of FloridaThe Medicines CompanyCompletedCoronary Artery DiseaseUnited States
-
University of FloridaAstraZenecaCompleted
-
Centro Hospitalario La ConcepcionRecruiting
-
Sheba Medical CenterCompletedST Elevation Myocardial Infarction | Acute Coronary SyndromesIsrael
-
David AntoniucciAstraZeneca; A.R. CARD Onlus FoundationCompletedAcute Coronary Syndrome | Adverse Reaction to Antiplatelet AgentItaly, Greece
-
AstraZenecaCompletedMyocardial Infarction | Stroke | Atherothrombosis | Cardiovascular DeathSweden, United States, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Peru, Poland, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Germany, Philippines, China, Hungary, Romania, U... and more